Tesamorelin: what it is, how it acts and what the studies show

Tesamorelin is a synthetic analogue of GHRH that stimulates endogenous GH secretion and increases IGF-1. In clinical studies in adults with HIV-associated lipodystrophy, a significant reduction in visceral fat (VAT) and improvement in body composition have been shown. The information is based on published research and data, as well as on our product page. Studies on tesamorelin

What is tesamorelin?

A peptide, a modified GHRH analogue. Unlike direct GH administration, tesamorelin induces pulsatile secretion of endogenous GH — a more “physiological” approach to the GH–IGF-1 axis.

Where it is approved: The pharmaceutical forms are approved in the US for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy; it is not intended for general weight loss. Tesamorelin - FDA Access Data

Mechanism of action: GH–IGF-1 axis

1. GHRH-R binding (anterior pituitary)
   
   
2. Pulsatile GH secretion (physiological dynamics)
   
   
3. Increase in IGF-1 → lipolysis, tissue remodelling, metabolic effects
   This explains the reduction in visceral fat observed in studies. See more about the study on the effects of tesamorelin.
   
   

What the studies show (in brief)

• Primary endpoints in RCTs: change in VAT and/or liver lipids; secondary: glycaemia and metabolic markers. Multiple studies report a significant reduction in VAT after 6–12 months.
  
• Data on a moderate reduction in liver lipids in subgroups (including steatosis).
  
• Tolerability: generally good; most often local injection-site reactions, arthralgia/myalgia, peripheral oedema; changes in glycaemia and an increase in IGF-1 are possible (monitoring required). Rarely: hypersensitivity, carpal tunnel syndrome, hyperglycaemia.
  
  

Benefits & applications (research & clinical)

• Reduction of visceral fat and improvement of body composition in HIV-associated lipodystrophy (approved indication of the pharmaceutical forms).
  
• Support for the GH–IGF-1 axis with possible benefits for recovery/metabolism (depending on the model/population).
  
• Liver metabolism: a reduction in liver lipids has been observed in some studies.
  
  

Note: the product at Peptology is intended exclusively for research use and is not a medicine. The content is educational and summarises study data.

See other peptides from the tesamorelin category in our “Recovery and Anabolic Peptides” category.

Safety profile

Common adverse events (AEs): local reactions (erythema, pain, itching), arthralgia/myalgia, peripheral oedema. Possible increases in IGF-1 and changes in glycaemic control (monitoring is recommended).
Warnings (based on medical information): active malignancy, pregnancy, hypersensitivity; not for weight loss outside the specific indication; the long-term cardiovascular safety of the pharmaceutical forms remains inconclusive.

Tesamorelin in the Peptology catalogue (research)

On the product page you will find a mechanism summary, key study data, FAQ and logistics information (delivery/storage). From there, see related GH-axis peptides (e.g. CJC-1295, Ipamorelin) for combination models.

Frequently Asked Questions (FAQ)

Tesamorelin = slimming?
No. The approved indication is HIV-associated lipodystrophy with excess abdominal fat — not general “weight loss”.

Difference from direct GH?
It is a GHRH analogue: it stimulates endogenous GH in a pulsatile way, not exogenous GH; it mimics GH–IGF-1 physiology better.

Most common adverse events?
Local reactions, arthralgia/myalgia, peripheral oedema; possible changes in glycaemia and an increase in IGF-1 (monitoring).

Disclaimer

The content is exclusively educational; it is not medical advice. Research products are not intended for human use.

Sources

1. Tesamorelin prescribing information — indications, contraindications, warnings, adverse events (AEs).
   
   
2. RCTs & reviews on VAT/liver lipids in HIV lipodystrophy (JAMA, The Lancet HIV, PMC).
   
   
3. LiverTox (NCBI) — safety profile, IGF-1, metabolic parameters.